Dysmetabolic changes associated with HCV: a distinct syndrome? (original) (raw)

References

1. Wong T, Lee SS (2006) Hepatitis C: a review for primary care physicians. CMAJ 174:649–659
   PubMed Google Scholar
2. Anonimymous (1999) EASL International Consensus Conference on Hepatitis C Paris, 26–27 February 1999 Consensus Statement Conference. J Hepatol 31:3–8
   Google Scholar
3. Wasley A, Alter MJ (2000) Epidemiology of hepatitis C: geographic differences and temporal trends. Semin Liver Dis20:1–16
   Google Scholar
4. Ansaldi F, Bruzzone B, Salmaso S, Rota MC, Durando P, Gasparini R, Icardi G (2005) Different seroprevalence and molecular epidemiology patterns of hepatitis C virus infection in Italy. J Med Virol 76:327–332
   PubMed CAS Google Scholar
5. Liang TJ, Rehermann B, Seeff LB, Hoofnagle JH (2000) Pathogenesis, natural history, treatment, and prevention of hepatitis C. Ann Intern Med 132:296–305
   PubMed CAS Google Scholar
6. Sene D, Limal N, Cacoub P (2004) Hepatitis C virus-associated extrahepatic manifestations: a review. Metab Brain Dis 19:357–381
   PubMed Google Scholar
7. Koike K, Moriya K (2005) Metabolic aspects of hepatitis C viral infection: steatohepatitis resembling but distinct from NASH. J Gastroenterol 40:329–336
   PubMed CAS Google Scholar
8. Bach N, Thung SN, Schaffner F (1992) The histological features of chronic hepatitis C and autoimmune chronic hepatitis: a comparative analysis. Hepatology 15:572–577
   PubMed CAS Google Scholar
9. Loria P, Lonardo A, Carulli L, Verrone AM, Ricchi M, Lombardini S, Rudilosso A, Ballestri S, Carulli N (2005) Review article: the metabolic syndrome and non-alcoholic fatty liver disease. Aliment Pharmacol Ther 22(Suppl 2):31–36
   PubMed Google Scholar
10. Reisin E, Alpert MA (2005) Definition of the metabolic syndrome: current proposals and controversies. Am J Med Sci 330:269–272
    PubMed Google Scholar
11. Zambon A, Pauletto P, Crepaldi G (2005) Review article: the metabolic syndrome—a chronic cardiovascular inflammatory condition. Aliment Pharmacol Ther 22(Suppl 2):20–23
    PubMed Google Scholar
12. Ahmed I, Goldstein BJ (2006) Cardiovascular risk in the spectrum of type 2 diabetes mellitus. Mt Sinai J Med 73:759–768
    PubMed Google Scholar
13. Cowey S, Hardy RW (2006) The metabolic syndrome: a high-risk state for cancer? Am J Pathol 169:1505–1522
    PubMed CAS Google Scholar
14. Choi J, Ou JH (2006) Mechanisms of liver injury. III. Oxidative stress in the pathogenesis of hepatitis C virus. Am J Physiol Gastrointest Liver Physiol 290:G847–G851
    PubMed CAS Google Scholar
15. Diaz JM, Sainz Z, Guirado LL, Ortiz-Herbener F, Picazo M, Garcia-Camin R, Palou J, Alcaraz A, Sola R (2003) Risk factors for cardiovascular disease after renal transplantation. Transplant Proc 35:1722–1724
    PubMed CAS Google Scholar
16. Seeff LB (1997) The natural history of chronic hepatitis C virus infection. Clin Liver Dis 1:587–602
    PubMed CAS Google Scholar
17. Ratziu V, Munteanu M, Charlotte F, Bonyhay L, Poynard T (2003) LIDO Study Group. Fibrogenic impact of high serum glucose in chronic hepatitis C. J Hepatol 39:1049–1055
    PubMed CAS Google Scholar
18. Lonardo A, Loria P, Adinolfi LE, Carulli N, Ruggiero G (2006) Hepatitis C and steatosis: a reappraisal. J Viral Hepat 13:73–80
    PubMed CAS Google Scholar
19. Adinolfi LE, Gambardella M, Andreana A, Tripodi MF, Utili R, Ruggiero G (2001) Steatosis accelerates the progression of liver damage of chronic hepatitis C patients and correlates with specific HCV genotype and visceral obesity. Hepatology 33:1358–1364
    PubMed CAS Google Scholar
20. Poynard T, Ratziu V, McHutchison J, Manns M, Goodman Z, Zeuzem S, Younossi Z, Albrecht J (2003) Effect of treatment with peginterferon or interferon alfa-2b and ribavirin on steatosis in patients infected with hepatitis C. Hepatology 38:75–85
    PubMed CAS Google Scholar
21. Lonardo A, Lombardini S, Scaglioni F, Carulli L, Ricchi M, Ganazzi D, Adinolfi LE, Ruggiero G, Carulli N, Loria P (2006) Hepatic steatosis and insulin resistance: does etiology make a difference? J Hepatol 44:190–196
    PubMed CAS Google Scholar
22. Shaheen M, Echeverry D, Oblad MG, Montoya MI, Teklehaimanot S, Akhtar AJ (2007) Hepatitis C, metabolic syndrome, and inflammatory markers: results from the Third National Health and Nutrition Examination Survey [NHANES III]. Diabetes Res Clin Pract 75:320–326
    PubMed Google Scholar
23. Lin TJ, Liao LY, Lin SY, Lin CL, Chang TA (2006) Influence of iron on the severity of hepatic fibrosis in patients with chronic hepatitis C. World J Gastroenterol 12:4897–4901
    PubMed CAS Google Scholar
24. Loria P, Lonardo A, Carulli N (2005) Should nonalcoholic fatty liver disease be renamed? Dig Dis 23:72–82
    PubMed Google Scholar
25. Zelber-Sagi S, Nitzan-Kaluski D, Halpern Z, Oren R (2007) NAFLD and hyperinsulinemia are major determinants of serum ferritin levels. J Hepatol 46:700–707
    PubMed CAS Google Scholar
26. Shintani Y, Fujie H, Miyoshi H, Tsutsumi T, Tsukamoto K, Kimura S, Moriya K, Koike K (2004) Hepatitis C virus infection and diabetes: direct involvement of the virus in the development of insulin resistance. Gastroenterology 126:840–848
    PubMed CAS Google Scholar
27. Delgado-Borrego A, Casson D, Schoenfeld D, Somsouk M, Terella A, Jordan SH, Bhan A, Baid S, Cosimi AB, Pascual M, Chung RT (2004) Hepatitis C virus is independently associated with increased insulin resistance after liver transplantation. Transplantation 77:703–710
    PubMed Google Scholar
28. Romero-Gomez M (2006) Hepatitis C and insulin resistance: steatosis, fibrosis and non-response. Rev Esp Enferm Dig 98:605–615
    Article PubMed CAS Google Scholar
29. Negro F (2006) Mechanisms and significance of liver steatosis in hepatitis C virus infection. World J Gastroenterol 12:6756–6765
    PubMed Google Scholar
30. Kawaguchi T, Yoshida T, Harada M, Hisamoto T, Nagao Y, Ide T, Taniguchi E, Kumemura H, Hanada S, Maeyama M, Baba S, Koga H, Kumashiro R, Ueno T, Ogata H,Yoshimura A, Sata M (2004) Hepatitis C virus down-regulates insulin receptor substrates 1 and 2 through up-regulation of suppressor of cytokine signaling 3. Am J Pathol 165:1499–1508
    PubMed CAS Google Scholar
31. Durante-Mangoni E, Zampino R, Marrone A, Tripodi MF, Rinaldi L, Restivo L, Cioffi M, Ruggiero G, Adinolfi LE (2006) Hepatic steatosis and insulin resistance are associated with serum imbalance of adiponectin/tumour necrosis factor-alpha in chronic hepatitis C patients. Aliment Pharmacol Ther 24:1349–1357
    PubMed CAS Google Scholar
32. Aytug S, Reich D, Sapiro LE, Bernstein D, Begum N (2003) Impaired IRS-1/PI3-kinase signaling in patients with HCV: a mechanism for increased prevalence of type 2 diabetes. Hepatology 38:1384–1392
    PubMed CAS Google Scholar
33. de Gottardi A, Pazienza V, Pugnale P, Bruttin F, Rubbia-Brandt L, Juge-Aubry CE, Meier CA, Hadengue A, Negro F (2006) Peroxisome proliferator-activated receptor-alpha and -gamma mRNA levels are reduced in chronic hepatitis C with steatosis and genotype 3 infection. Aliment Pharmacol Ther 23:107–114
    PubMed Google Scholar
34. Lonardo A, Carulli N and Loria P (2007) HCV and diabetes. A 2 question-based reappraisal. Dig Liver Dis. doi:10.1016/j.dld.2007.05.005
35. Walsh MJ, Jonsson JR, Richardson MM, Lipka GM, Purdie DM, Clouston AD, Powell EE (2006) Non-response to antiviral therapy is associated with obesity and increased hepatic expression of suppressor of cytokine signalling 3 (SOCS-3) in patients with chronic hepatitis C, viral genotype 1. Gut 55:529–535. Epub 18 Nov 2005
    PubMed CAS Google Scholar
36. Naunyn B (1898) Glykosurie und Diabetes durch experimentelle Insulte und Krankheiten der Leber. In: Nothnagel E (ed) Der Diabetes mellitus in Handbuch. Spez Path Ther Bd 7. Holder A, Wien, pp 38–49
37. Allison ME, Wreghitt T, Palmer CR, Alexander GJ (1994) Evidence for a link between hepatitis C virus infection and diabetes mellitus in a cirrhotic population. J Hepatol 21:1135–1139
    PubMed CAS Google Scholar
38. Ozyilkan E, Arslan M (1996) Increased prevalence of diabetes mellitus in patients with chronic hepatitis C virus infection. Am J Gastroenterol 91:1480–1481
    PubMed CAS Google Scholar
39. Del Olmo JA, Serra MA, Rodrigo JM (1996) Liver cirrhosis and diabetes mellitus. J Hepatol 24:645
    PubMed Google Scholar
40. Grimbert S, Valensi P, Levy-Marchal C, Perret G, Richardet JP, Raffoux C, Trinchet JC, Beaugrand M (1996) High prevalence of diabetes mellitus in patients with chronic hepatitis C. A case-control study. Gastroenterol Clin Biol 20:544–548
    PubMed CAS Google Scholar
41. Fraser GM, Harman I, Meller N, Niv Y, Porath A (1996) Diabetes mellitus is associated with chronic hepatitis C but not chronic hepatitis B infection. Isr J Med Sci 32:526–530
    PubMed CAS Google Scholar
42. Mangia A, Schiavone G, Lezzi G, Marmo R, Bruno F, Villani MR, Cascavilla I, Fantasia L, Andriulli A (1998) HCV and diabetes mellitus: evidence for a negative association. Am J Gastroenterol 93:2363–2367
    PubMed CAS Google Scholar
43. Mason AL, Lau JY, Hoang N, Qian K, Alexander GJ, Xu L, Guo L, Jacob S, Regenstein FG, Zimmerman R, Everhart JE, Wasserfall C, Maclaren NK, Perrillo RP (1999) Association of diabetes mellitus and chronic hepatitis C virus infection. Hepatology 29:328–333
    PubMed CAS Google Scholar
44. Caronia S, Taylor K, Pagliaro L, Carr C, Palazzo U, Petrik J, O’Rahilly S, Shore S, Tom BD, Alexander GJ (1999) Further evidence for an association between non-insulin-dependent diabetes mellitus and chronic hepatitis C virus infection. Hepatology 30:1059–1063
    PubMed CAS Google Scholar
45. Macedo G, Ribeiro T (1999) Cirrhosis and diabetes: C, the difference. Am J Gastroenterol 94:3088–3089
    PubMed CAS Google Scholar
46. Labropoulou-Karatza C, Goritsas C, Fragopanagou H, Repandi M, Matsouka P, Alexandrides T (1999) High prevalence of diabetes mellitus among adult beta-thalassaemic patients with chronic hepatitis C. Eur J Gastroenterol Hepatol 11:1033–1036
    PubMed CAS Google Scholar
47. Knobler H, Schihmanter R, Zifroni A, Fenakel G, Schattner A (2000) Increased risk of type 2 diabetes in noncirrhotic patients with chronic hepatitis C virus infection. Mayo Clin Proc 75:355–359
    Article PubMed CAS Google Scholar
48. Zein NN, Abdulkarim AS, Wiesner RH, Egan KS, Persing DH (2000) Prevalence of diabetes mellitus in patients with end-stage liver cirrhosis due to hepatitis C, alcohol, or cholestatic disease. J Hepatol 32:209–217
    PubMed CAS Google Scholar
49. Arao M, Murase K, Kusakabe A, Yoshioka K, Fukuzawa Y, Ishikawa T, Tagaya T, Yamanouchi K, Ichimiya H, Sameshima Y, Kakumu S (2003) Prevalence of diabetes mellitus in Japanese patients infected chronically with hepatitis C virus. J Gastroenterol 38:355–360
    PubMed Google Scholar
50. Wang CS, Wang ST, Yao WJ, Chang TT, Chou P (2003) Community-based study of hepatitis C virus infection and type 2 diabetes: an association affected by age and hepatitis severity status. Am J Epidemiol 158:1154–1160
    PubMed Google Scholar
51. Lecube A, Hernandez C, Genesca J, Esteban JI, Jardi R, Simo R (2004) High prevalence of glucose abnormalities in patients with hepatitis C virus infection. Diabetes Care 27:1171–1175
    PubMed CAS Google Scholar
52. Kwon SY, Kim SS, Kwon OS, Kwon KA, Chung MG, Park DK, Kim YS, Koo YS, Kim YK, Choi DJ, Kim JH (2005) Prognostic significance of glycaemic control in patients with HBV and HCV-related cirrhosis and diabetes mellitus. Diabet Med 22:1530–1535
    PubMed CAS Google Scholar
53. Wilson C (2004) Hepatitis C infection and type 2 diabetes in American-Indian women. Diabetes Care 27:2116–2119
    PubMed Google Scholar
54. Alavian SM, Hajarizadeh B, Nematizadeh F, Larijani B (2004) Prevalence and determinants of diabetes mellitus among Iranian patients with chronic liver disease. BMC Endocr Disord 4:4
    PubMed Google Scholar
55. Antonelli A, Ferri C, Fallahi P, Sebastiani M, Nesti C, Barani L, Barale R, Ferrannini E (2004) Type 2 diabetes in hepatitis C-related mixed cryoglobulinaemia patients. Rheumatology (Oxford) 43:238–240
    CAS Google Scholar
56. Papatheodoridis GV, Chrysanthos N, Savvas S, Sevastianos V, Kafiri G, Petraki K, Manesis EK (2006) Diabetes mellitus in chronic hepatitis B and C: prevalence and potential association with the extent of liver fibrosis. J Viral Hepat 13:303–310
    PubMed CAS Google Scholar
57. Antonelli A, Ferri C, Fallahi P, Pampana A, Ferrari SM, Goglia F, Ferrannini (2005) Hepatitis C virus infection: evidence for an association with type 2 diabetes. Diabetes Care 28:2548–2550
    PubMed Google Scholar
58. Zein CO, Levy C, Basu A, Zein NN (2005) Chronic hepatitis C and type II diabetes mellitus: a prospective cross-sectional study. Am J Gastroenterol 100:48–55
    PubMed Google Scholar
59. Zhao P, Wang JB, Jiao J (2006) Investigation on the incidence of diabetes in chronic hepatitis C patients and their HCV genotypes. Zhonghua Gan Zang Bing Za Zhi 14:86–88
    PubMed Google Scholar
60. Mehta SH, Brancati FL, Sulkowski MS, Strathdee SA, Szklo M, Thomas DL (2000) Prevalence of type 2 diabetes mellitus among persons with hepatitis C virus infection in the United States. Ann Intern Med 133:592–599
    PubMed CAS Google Scholar
61. Mehta SH, Brancati FL, Strathdee SA, Pankow JS, Netski D, Coresh J, Szklo M, Thomas DL (2003) Hepatitis C virus infection and incident type 2 diabetes. Hepatology 38:50–56
    PubMed Google Scholar
62. El-Serag HB, Hampel H, Yeh C, Rabeneck L (2002) Extrahepatic manifestations of hepatitis C among United States male veterans. Hepatology 36:1439–1445
    PubMed Google Scholar
63. Gray H, Wreghitt T, Stratton IM, Alexander GJ, Turner RC, O’Rahilly S (1995) High Prevalence of hepatitis C infection in Afro-Caribbean patients with type 2 diabetes and abnormal liver function tests. Diabet Med 12:244–249
    Article PubMed CAS Google Scholar
64. Simo R, Hernandez C, Genesca J, Jardi R, Mesa J (1996) High prevalence of hepatitis C virus infection in diabetic patients. Diabetes Care 19:998–1000
    PubMed CAS Google Scholar
65. Soma J, Saito T, Taguma Y, Chiba S, Sato H, Sugimura K et al (2000) High Prevalence and adverse effects of hepatitis C virus infection in type II diabetic-related nephropathy. J Am Soc Nephrol 11:690–699
    PubMed CAS Google Scholar
66. Sotiropoulos A, Peppas TA, Skliros E, Apostolou O, Kotsini V, Pappas SI (1999) Low prevalence of hepatitis C virus infection in Greek diabetic patients. Diab Med 16:250–252
    CAS Google Scholar
67. Balogun WO, Adeleyde JO, Akinklade KS, Kuti M, Otegbayoe JA (2006) Low prevalence of hepatitis-C viral seropositivity among patients with type-2 diabetes mellitus in a tertiary hospital. J Natl Med Assoc 98:1805–1808
    PubMed Google Scholar
68. Behrendt CE, Ruiz RB (2006) Hyperglycemia among persons with hepatitis C: not the classical diabetic phenotype. Diabetes Res Clin Pract 71:68–74
    PubMed CAS Google Scholar
69. Fartoux L, Poujol-Robert A, Guechot J, Wendum D, Poupon R, Serfaty L (2005) Insulin resistance is a cause of steatosis and fibrosis progression in chronic hepatitis C. Gut 54:1003–1008
    PubMed CAS Google Scholar
70. Bugianesi E, Marchesini G, Gentilcore E, Cua IH, Vanni E, Rizzetto M, George J (2006) Fibrosis in genotype 3 chronic hepatitis C and nonalcoholic fatty liver disease: Role of insulin resistance and hepatic steatosis. Hepatology 44:1648–1655
    PubMed CAS Google Scholar
71. Romero-Gomez M, Del Mar Viloria M, Andrade RJ, Salmeron J, Diago M, Fernandez-Rodriguez CM, Corpas R, Cruz M, Grande L, Vazquez L, Munoz-De-Rueda P, Lopez-Serrano P, Gila A, Gutierrez ML, Perez C, Ruiz-Extremera A, Suarez E, Castillo J (2005) Insulin resistance impairs sustained response rate to peginterferon plus ribavirin in chronic hepatitis C patients. Gastroenterology 128:636–641
    PubMed CAS Google Scholar
72. D’Souza R, Sabin CA, Foster GR (2005) Insulin resistance plays a significant role in liver fibrosis in chronic hepatitis C and in the response to antiviral therapy. Am J Gastroenterol 100:1509–1515
    PubMed CAS Google Scholar
73. Davila JA, Morgan RO, Shaib Y, McGlynn KA, El-Serag HB (2005) Diabetes increases the risk of hepatocellular carcinoma in the United States: a population based case control study. Gut 54:533–539
    PubMed CAS Google Scholar
74. Trombetta M, Spiazzi G, Zoppini G, Muggeo M (2005) Review article: type 2 diabetes and chronic liver disease in the Verona diabetes study. Aliment Pharmacol Ther 22(Suppl 2):24–27
    PubMed Google Scholar
75. Levrero M (2006) Viral hepatitis and liver cancer: the case of hepatitis C. Oncogene 25:3834–3847
    PubMed CAS Google Scholar
76. Vollenweider P (2003) Insulin resistant states and insulin signaling. Clin Chem Lab Med 41:1107–1119
    PubMed CAS Google Scholar
77. Chang CK, Ulrich CM (2003) Hyperinsulinaemia and hyperglycaemia: possible risk factors of colorectal cancer among diabetic patients. Diabetologia 46:595–607
    PubMed CAS Google Scholar
78. Thomssen R, Bonk S, Propfe C, Heermann KH, Kochel HG, Uy A (1992) Association of hepatitis C virus in human sera with beta-lipoprotein. Med Microbiol Immunol (Berl) 181:293–300
    CAS Google Scholar
79. Schettler V, Monazahian M, Wieland E, Ramadori G, Grunewald RW, Thomssen R, Muller GA (2001) Reduction of hepatitis C virus load by H.E.L.P.-LDL apheresis. Eur J Clin Invest 31:154–155
    PubMed CAS Google Scholar
80. Diedrich G (2006) How does hepatitis C virus enter cells? FEBS J 273:3871–3885
    PubMed CAS Google Scholar
81. Agnello V, Abel G, Elfahal M, Knight GB, Zhang QX (1999) Hepatitis C virus and other flaviviridae viruses enter cells via low density lipoprotein receptor. Proc Natl Acad Sci USA 96:12766–12771
    PubMed CAS Google Scholar
82. Gopal K, Johnson TC, Gopal S, Walfish A, Bang CT, Suwandhi P, Pena-Sahdala HN, Clain DJ, Bodenheimer HC Jr, Min AD (2006) Correlation between beta-lipoprotein levels and outcome of hepatitis C treatment. Hepatology 44:335–340
    PubMed CAS Google Scholar
83. Carre D, Boucher E, Turlin B, Guyader D, Brissot P, Deugnier Y (1994) [Decrease of cholesterolemia and apolipoprotein B in chronic viral hepatitis C with massive steatosis]. Gastroenterol Clin Biol 18:899–900
    PubMed CAS Google Scholar
84. Maggi G, Bottelli R, Gola D, Perricone G, Posca M, Zavaglia C, Ideo G (1996) Serum cholesterol and chronic hepatitis C. Ital J Gastroenterol 28:436–440
    PubMed CAS Google Scholar
85. Serfaty L, Andreani T, Giral P, Carbonell N, Chazouilleres O, Poupon R (2001) Hepatitis C virus induced hypobetalipoproteinemia: a possible mechanism for steatosis in chronic hepatitis C. J Hepatol 34:428–434
    PubMed CAS Google Scholar
86. Hofer H, Bankl HC, Wrba F, Steindl-Munda P, Peck-Radosavljevic M, Osterreicher C, Mueller C, Gangl A, Ferenci P (2002) Hepatocellular fat accumulation and low serum cholesterol in patients infected with HCV-3a. Am J Gastroenterol 97:2880–2885
    PubMed CAS Google Scholar
87. Fernandez-Rodriguez CM, Lopez-Serrano P, Alonso S, Gutierrez ML, Lledo JL, Perez-Calle JL, Temino R, Cacho G, Nevado M, Casas ML, Gasalla JM, Bonet B (2006) Long-term reversal of hypocholesterolaemia in patients with chronic hepatitis C is related to sustained viral response and viral genotype. Aliment Pharmacol Ther 24:507–512
    PubMed CAS Google Scholar
88. Hui JM, Kench J, Farrell GC, Lin R, Samarasinghe D, Liddle C, Byth K, George J (2002) Genotype-specific mechanisms for hepatic steatosis in chronic hepatitis C infection. J Gastroenterol Hepatol 17:873–881
    PubMed Google Scholar
89. Akuta N, Suzuki F, Kawamura Y, Yatsuji H, Sezaki H, Suzuki Y, Hosaka T, Kobayashi M, Kobayashi M, Arase Y, Ikeda K, Kumada H (2007) Predictive factors of early and sustained responses to peginterferon plus ribavirin combination therapy in Japanese patients infected with hepatitis C virus genotype 1b: amino acid substitutions in the core region and low-density lipoprotein cholesterol levels. J Hepatol 46:403–410
    PubMed CAS Google Scholar
90. Mirandola S, Realdon S, Iqbal J, Gerotto M, Dal Pero F, Bortoletto G, Marcolongo M, Vario A, Datz C, Hussain MM, Alberti A (2006) Liver microsomal triglyceride transfer protein is involved in hepatitis C liver steatosis. Gastroenterology 130:1661–1669
    PubMed CAS Google Scholar
91. Ikeda M, Abe K, Yamada M, Dansako H, Naka K, Kato N (2006) Different anti-HCV profiles of statins and their potential for combination therapy with interferon. Hepatology 44:117–125
    PubMed CAS Google Scholar
92. Brown MS, Goldstein JL (1981) Lowering plasma cholesterol by raising LDL receptors. N Engl J Med 305:515–517
    Article PubMed CAS Google Scholar
93. Monazahian M, Bohme I, Bonk S, Koch A, Scholz C, Grethe S, Thomssen R (1999) Low density lipoprotein receptor as a candidate receptor for hepatitis C virus. J Med Virol 57:223–229
    PubMed CAS Google Scholar
94. Lonardo A, Adinolfi LE, Loria P, Carulli N, Ruggiero G, Day CP (2004) Steatosis and hepatitis C virus: mechanisms and significance for hepatic and extrahepatic disease. Gastroenterology 126:586–597
    PubMed CAS Google Scholar
95. Lonardo A, Loria P, Bertolotti M., Carulli N (2007) Statins and HCV: a complex issue. Hepatology 45:257
    PubMed Google Scholar
96. Kiechl S, Egger G, Mayr M, Wiedermann CJ, Bonora E, Oberhollenzer F, Muggeo M, Xu Q, Wick G, Poewe W, Willeit J (2001) Chronic infections and the risk of carotid atherosclerosis: prospective results from a large population study. Circulation 103:1064–1070
    PubMed CAS Google Scholar
97. Bilora F, Rinaldi R, Boccioletti V, Petrobelli F, Girolami A (2002) Chronic viral hepatitis: a prospective factor against atherosclerosis. A study with echo-color Doppler of the carotid and femoral arteries and the abdominal aorta. Gastroenterol Clin Biol 26:1001–1004
    PubMed CAS Google Scholar
98. Ishizaka N, Ishizaka Y, Takahashi E, Tooda E, Hashimoto H, Nagai R, Yamakado M (2002) Association between hepatitis C virus seropositivity, carotid-artery plaque, and intima-media thickening. Lancet 359:133–135
    PubMed Google Scholar
99. Ishizaka Y, Ishizaka N, Takahashi E, Unuma T, Tooda E, Hashimoto H, Nagai R, Yamakado M (2003) Association between hepatitis C virus core protein and carotid atherosclerosis. Circ J 67:26–30
    PubMed CAS Google Scholar
100. Vassalle C, Masini S, Bianchi F, Zucchelli GC (2004) Evidence for association between hepatitis C virus seropositivity and coronary artery disease. Heart 90:565–566
     PubMed CAS Google Scholar
101. Haji SA, Starling RC, Avery RK, Mawhorter S, Tuzcu EM, Schoenhagen P, Cook DJ, Ratliff NB, McCarthy PM, Young JB, Yamani MH (2004) Donor hepatitis-C seropositivity is an independent risk factor for the development of accelerated coronary vasculopathy and predicts outcome after cardiac transplantation. J Heart Lung Transplant 23:277–283
     PubMed Google Scholar
102. Volzke H, Schwahn C, Wolff B, Mentel R, Robinson DM, Kleine V, Felix SB, John U (2004) Hepatitis B and C virus infection and the risk of atherosclerosis in a general population. Atherosclerosis 174:99–103
     PubMed Google Scholar
103. Arcari CM, Nelson KE, Netski DM, Nieto FJ, Gaydos CA (2006) No association between hepatitis C virus seropositivity and acute myocardial infarction. Clin Infect Dis 43:e53–e56
     PubMed Google Scholar
104. Sawayama Y, Okada K, Maeda S, Ohnishi H, Furusyo N, Hayashi J (2006) Both hepatitis C virus and Chlamydia pneumoniae infection are related to the progression of carotid atherosclerosis in patients undergoing lipid lowering therapy. Fukuoka Igaku Zasshi 97:245–255
     PubMed Google Scholar
105. Targher G, Bertolini L, Padovani R, Rodella S, Arcaro G, Day C (2007) Differences and similarities in early atherosclerosis between patients with non-alcoholic steatohepatitis and chronic hepatitis B and C. J Hepatol 46:1126–1132
     PubMed CAS Google Scholar
106. Liao KF, Peng CY, Lai SW, Chang WL, Hsu NY (2006) Descriptive epidemiology of hepatitis C virus among male heroin abusers in Taiwan. South Med J 99:348–351
     PubMed Google Scholar
107. Marchesini G, Ronchi M, Forlani G, Bugianesi E, Bianchi G, Fabbri A, Zoli M, Melchionda N (1999) Cardiovascular disease in cirrhosis—a point-prevalence study in relation to glucose tolerance. Am J Gastroenterol 94:655–662
     PubMed CAS Google Scholar
108. Palomo I, Alarcon M, Moore-Carrasco R, Argiles JM (2006) Hemostasis alterations in metabolic syndrome. Int J Mol Med 18:969–974
     PubMed CAS Google Scholar
109. Mato JM, Lu SC (2005) Homocysteine, the bad thiol. Hepatology 41:976–979
     PubMed Google Scholar
110. Adinolfi LE, Ingrosso D, Cesaro G, Cimmino A, D’Anto M, Capasso R, Zappia V, Ruggiero G (2005) Hyperhomocysteinemia and the MTHFR C677T polymorphism promote steatosis and fibrosis in chronic hepatitis C patients. Hepatology 41:995–1003
     PubMed CAS Google Scholar
111. Ratziu V, Trabut JB, Poynard T (2004) Fat, diabetes, and liver injury in chronic hepatitis C. Curr Gastroenterol Rep 6:22–29
     PubMed Google Scholar
112. Wisniewska-Ligier M, Wozniakowska-Gesicka T, Kups J, Sulat-Syncerek D (2006) Lipid metabolism in children with chronic hepatitis C, A preliminary report. Hepatogastroenterology 53:887–891
     PubMed CAS Google Scholar
113. Hu KQ, Kyulo NL, Esrailian E, Thompson K, Chase R, Hillebrand DJ, Runyon BA (2004) Overweight and obesity, hepatic steatosis, and progression of chronic hepatitis C: a retrospective study on a large cohort of patients in the United States. J Hepatol 40:147–154
     PubMed CAS Google Scholar
114. Solis-Herruzo JA, Perez-Carreras M, Rivas E, Fernandez-Vazquez I, Garfia C, Bernardos E, Castellano G, Colina F (2005) Factors associated with the presence of nonalcoholic steatohepatitis in patients with chronic hepatitis C. Am J Gastroenterol 100:1091–1098
     PubMed Google Scholar
115. Romero-Gomez M, Castellano-Megias VM, Grande L, Irles JA, Cruz M, Nogales MC, Alcon JC, Robles A (2003) Serum leptin levels correlate with hepatic steatosis in chronic hepatitis C. Am J Gastroenterol 98:1135–1141
     PubMed CAS Google Scholar
116. McCullough AJ (2003) Obesity and its nurturing effect on hepatitis C. Hepatology 38:557–559
     PubMed Google Scholar
117. Cacoub P, Poynard T, Ghillani P, Charlotte F, Olivi M, Piette JC, Opolon P (1999) Extrahepatic manifestations of chronic hepatitis C. MULTIVIRC Group. Multidepartment Virus C. Arthritis Rheum 42:2204–2212
     PubMed CAS Google Scholar
118. Poynard T, Cacoub P, Ratziu V, Myers RP, Dezailles MH, Mercadier A, Ghillani P, Charlotte F, Piette JC, Moussalli J (2002) Multivirc group. Fatigue in patients with chronic hepatitis C. J Viral Hepat 9:295–303
     PubMed CAS Google Scholar
119. Tarantino G, Conca P, Sorrentino P, Ariello M (2006) Metabolic factors involved in the therapeutic response of patients with hepatitis C virus-related chronic hepatitis. J Gastroenterol Hepatol 21:1266–1268
     PubMed CAS Google Scholar
120. Tsouli SG, Liberopoulos EN, Mikhailidis DP, Athyros VG, Elisaf MS (2006) Elevated serum uric acid levels in metabolic syndrome: an active component or an innocent bystander? Metabolism 55:1293–1301
     PubMed CAS Google Scholar
121. Grassi A, Ballardini G, Susca M, Bianchini F, Bonoli S, Bianchi FB, Lenzi M (2005) HCV liver infection and liver steatosis: evidence for indirect mechanisms in genotype 3? Aliment Pharmacol Ther 22(Suppl 2):79–82
     PubMed Google Scholar
122. Stanzial AM, Benoni G, Cuzzolin L, Gabrielli GB, Pasino M, Perfetti P, Corrocher R (2003) Urinary nitrite/nitrate concentrations and total antioxidant capacity in patients with chronic hepatitis C in therapy with interferon and ribavirin. J Chemother 15:584–590
     PubMed CAS Google Scholar
123. Hickman IJ, Jonsson JR, Prins JB, Ash S, Purdie DM, Clouston AD, Powell EE (2004) Modest weight loss and physical activity in overweight patients with chronic liver disease results in sustained improvements in alanine aminotransferase, fasting insulin, and quality of life. Gut 53:413–419
     PubMed CAS Google Scholar

Download references